Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases

Basit Öğe Kaydı
dc.authorid0000-0002-7931-2941en_US
dc.authorid0000-0003-0882-0524en_US
dc.authorid0000-0002-0878-6525en_US
dc.authorid0000-0002-7451-2786en_US
dc.contributor.authorOruç, Zeynep
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorKaraağac, Mustafa
dc.contributor.authorÖzyurt, Neslihan
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorKut, Engin
dc.contributor.authorKoca, Sinan
dc.contributor.authorSever, Özlem Nuray
dc.contributor.authorYasin, İrem
dc.contributor.authorEbinç, Senar
dc.contributor.authorZeynelgil, Esra
dc.contributor.authorSakin, Abdullah
dc.contributor.authorTurhal, Nazım Serdar
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2022-06-03T12:21:21Z
dc.date.available2022-06-03T12:21:21Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Onkoloji Ana Bilim Dalıen_US
dc.descriptionWOS:000621799100001
dc.descriptionPMID: 33631986
dc.description.abstractAim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival. Lay abstract The optimal therapeutic option for castration-resistant prostate cancer (CRPC) patients with visceral metastases is unknown. We assessed the efficacy and tolerability of the first-line treatment options for CRPC patients with visceral metastasis. One hundred ninety-one patients diagnosed with CRPC with visceral metastases were included in the study. The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival between first-line docetaxel, abiraterone and enzalutamide treatments in CRPC patients with visceral metastases. For patients who cannot undergo chemotherapy, enzalutamide, among novel androgen pathway inhibitors, may be the most appropriate option, given its numerical, although statistically insignificant, difference in overall survival and its fewer side effects compared with abiraterone.en_US
dc.identifier.citationOruç, Z., Kaplan, M.A., Karaağac, M., Özyurt, N., Tatlı, A.M., Kaya, A.O. ve diğerleri. (2021). Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncology, 17(13), 1611-1624.en_US
dc.identifier.doi10.2217/fon-2020-1032
dc.identifier.endpage1624en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue13en_US
dc.identifier.pmid33631986
dc.identifier.scopus2-s2.0-85103985285
dc.identifier.scopusqualityQ2
dc.identifier.startpage1611en_US
dc.identifier.urihttps://www.futuremedicine.com/doi/10.2217/fon-2020-1032
dc.identifier.urihttps://hdl.handle.net/11468/9962
dc.identifier.volume17en_US
dc.identifier.wosWOS:000621799100001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorOruç, Zeynep
dc.institutionauthorKaplan, M. Ali
dc.institutionauthorEbinç, Senar
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherFuture Medicine LTD.en_US
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHormone-refractory diseaseen_US
dc.subjectProstate canceren_US
dc.subjectVisceral metastasisen_US
dc.titleEfficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastasesen_US
dc.titleEfficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu